#moleculardiagnostics

  1. What Analysts Are Saying About DermTech Stock

    By Benzinga Insights DermTech (NASDAQ: DMTK ) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments ov
  2. Peeling Back The Layers: Exploring Myriad Genetics Through Analyst Insights

    By Benzinga Insights Across the recent three months, 5 analysts have shared their insights on Myriad Genetics (NASDAQ: MYGN ), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolvin